SpringWorks Therapeutics, Inc. (SWTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 26.02 |
| Open | 25.96 |
| Bid | 24.95 x 800 |
| Ask | 26.07 x 800 |
| Day's Range | 24.75 - 26.14 |
| 52 Week Range | 13.60 - 63.68 |
| Volume | |
| Avg. Volume | 736,129 |
| Market Cap | 1.561B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SWTX
Related Research
- SpringWorks Therapeutics, Inc.Daily – Vickers Top Insider Picks for 03/29/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moatlast yearArgus Research
- Benzinga
HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging
Ayala Pharmaceuticals Inc (NASDAQ: Ayala) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. HC Wainwright reiterated the Buy rating on the stock with a price target of $18. The analyst says that Ayala's initial data is encouraging in the context of the clinical devel
- Benzinga
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80% and 87% of medical oncologists believe that nirogacestat compares favorably to Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) and that they are willing to switch current patients to nirogacestat, respectively. The analysts for
- Zacks
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
